These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 17955251)

  • 1. [Osteoporosis and bisphosphonates].
    Zuber MA
    Z Rheumatol; 2007 Dec; 66(8):713-5. PubMed ID: 17955251
    [No Abstract]   [Full Text] [Related]  

  • 2. [Atrial fibrillation during bisphosphonate therapy. side effects or coincidental finding?].
    Ringe JD
    MMW Fortschr Med; 2009 Mar; 151(10):7. PubMed ID: 19472655
    [No Abstract]   [Full Text] [Related]  

  • 3. Bisphosphonates and atrial fibrillation.
    Prescrire Int; 2008 Aug; 17(96):161. PubMed ID: 19492493
    [No Abstract]   [Full Text] [Related]  

  • 4. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug; 17(96):143. PubMed ID: 19480098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Annual zoledronic acid for osteoporosis.
    BMJ Group
    Drug Ther Bull; 2008 Dec; 46(12):93-6. PubMed ID: 19056701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treating with what? Therapy for how long?].
    MMW Fortschr Med; 2005 Dec; 147(51-52):62-3. PubMed ID: 16402713
    [No Abstract]   [Full Text] [Related]  

  • 8. A once-yearly IV bisphosphonate for osteoporosis.
    Med Lett Drugs Ther; 2007 Nov; 49(1273):89-90. PubMed ID: 17975523
    [No Abstract]   [Full Text] [Related]  

  • 9. Yearly zoledronic acid in postmenopausal osteoporosis.
    Karam R; Camm J; McClung M
    N Engl J Med; 2007 Aug; 357(7):712-3; author reply 714-5. PubMed ID: 17703529
    [No Abstract]   [Full Text] [Related]  

  • 10. A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.
    Hagino H; Nishizawa Y; Sone T; Morii H; Taketani Y; Nakamura T; Itabashi A; Mizunuma H; Ohashi Y; Shiraki M; Minamide T; Matsumoto T
    Bone; 2009 Jun; 44(6):1078-84. PubMed ID: 19264155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate and atrial fibrillation.
    Cummings SR; Schwartz AV; Black DM
    N Engl J Med; 2007 May; 356(18):1895-6. PubMed ID: 17476024
    [No Abstract]   [Full Text] [Related]  

  • 12. [Diphosphonate therapy and osteonecrosis of the jaw].
    Løkken P; Skoglund LA; Skjelbred P
    Tidsskr Nor Laegeforen; 2007 Aug; 127(15):1945-7. PubMed ID: 17700737
    [No Abstract]   [Full Text] [Related]  

  • 13. Biennial [corrected] IV zoledronic acid (Reclast) for prevention of osteoporosis.
    Med Lett Drugs Ther; 2009 Jun; 51(1315):49. PubMed ID: 19556940
    [No Abstract]   [Full Text] [Related]  

  • 14. Yearly zoledronic acid in postmenopausal osteoporosis.
    de Nijs RN; Westgeest AA
    N Engl J Med; 2007 Aug; 357(7):711; author reply 714-5. PubMed ID: 17699824
    [No Abstract]   [Full Text] [Related]  

  • 15. Going on a drug holiday?
    Bonnick SL
    J Clin Densitom; 2011; 14(4):377-83. PubMed ID: 22051091
    [No Abstract]   [Full Text] [Related]  

  • 16. [Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
    MMW Fortschr Med; 2006 Jun; 148(25):60-1. PubMed ID: 16859169
    [No Abstract]   [Full Text] [Related]  

  • 17. What do we know about the ocular adverse effects associated with intravenous bisphosphonates?
    Atik OS
    Eklem Hastalik Cerrahisi; 2011; 22(1):1. PubMed ID: 21417978
    [No Abstract]   [Full Text] [Related]  

  • 18. [Inflammation of the jaws during treatment with bisphosphonates].
    Bartl R
    Dtsch Med Wochenschr; 2011 Oct; 136(41):2109-10. PubMed ID: 21971888
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation following intravenous zolendronic acid for osteoporosis.
    Konsta M; Bournia VK; Dania V; Iliopoulos A
    J Clin Rheumatol; 2014 Jun; 20(4):239-40. PubMed ID: 24847757
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.